Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses.
about
Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primatesAnimal models for Ebola and Marburg virus infectionsEbola virus entry requires the host-programmed recognition of an intracellular receptorNeglected filovirusesAd35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus speciesEbola and Marburg virus vaccines.Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirusDevelopment and characterization of a mouse model for Marburg hemorrhagic feverA replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challengeVector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primatesLassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.Mechanisms of immunity in post-exposure vaccination against Ebola virus infection.Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles.Advances in virus-like particle vaccines for filoviruses.Clinical aspects of Marburg hemorrhagic feverRecombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infectionsFilovirus vaccines.A Comparison of the Pathogenesis of Marburg Virus Disease in Humans and Nonhuman Primates and Evaluation of the Suitability of These Animal Models for Predicting Clinical Efficacy under the 'Animal Rule'.Comparison of the Pathogenesis of the Angola and Ravn Strains of Marburg Virus in the Outbred Guinea Pig Model.Prospects for immunisation against Marburg and Ebola viruses.Progress in filovirus vaccine development: evaluating the potential for clinical use.Forty-five years of Marburg virus research.Potential vaccines and post-exposure treatments for filovirus infections.Adjuvant-enhanced CD4 T Cell Responses are Critical to Durable Vaccine ImmunityVirus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges).Vaccines for viral hemorrhagic fevers--progress and shortcomingsDiscovery of common marburgvirus protective epitopes in a BALB/c mouse model.The non-human primate model of tuberculosis.Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.Ebola virus disease candidate vaccines under evaluation in clinical trials.Ebola Virus Glycoprotein Induces an Innate Immune Response In vivo via TLR4Niemann-Pick C1 (NPC1)/NPC1-like1 chimeras define sequences critical for NPC1's function as a flovirus entry receptor.Immune Response to Marburg Virus Angola Infection in Nonhuman Primates.Marburg virus-like particles by co-expression of glycoprotein and matrix protein in insect cells induces immune responses in miceChallenges, progress, and opportunities: proceedings of the filovirus medical countermeasures workshop.
P2860
Q21090120-198995FF-AF1B-481E-BB63-E833FAE1468DQ21131118-DBF9F4E3-ABB6-43CF-A037-24C0EAABD448Q24629282-D5972534-0623-4B6C-AEC0-54DC47398F20Q28383265-DE4EE729-6705-46CA-A444-ED7509A6E3E3Q28485505-E7B3EA76-6598-4E58-8882-1077A83F1959Q30234637-D6D2FEFE-A6E6-4CCC-B573-08331146E8E2Q30724121-CB455E8A-AFAC-42E5-B05D-E8E86E7A1A55Q33384111-4B27836C-F8B3-44DF-90DE-4BE888F7C0F1Q33621078-70992B41-FF81-4F8D-949C-BD4CDEB0E993Q34120895-06563C19-0B77-4D98-9D35-64B7C3A5307FQ34322342-BD09295D-0302-4084-BC7F-F6E5B7F9A97CQ35192417-60EFBEE0-6B37-495E-AA6F-5FDC90B256EDQ35202880-88E21443-E6E5-4892-8975-26D4D7930F68Q35300029-A6867D24-41BB-453D-8392-227B46AC90ABQ35446144-B45DF684-E7BF-4931-8694-60C306ACC2DCQ35557184-0C4ACB3F-38CB-41CC-9F42-96E6EF40B467Q35558539-19D88EBF-4FA0-4712-8B2E-B012AB08E25EQ35798489-8AC902BF-E797-4266-8566-385926931BFDQ36043232-7AB4D16A-B9AE-404F-8655-21F0354739BAQ36088118-F3BD23FD-F5B1-4788-8028-9002369307C6Q36100545-A7F878DB-6E87-4752-B126-033F43C9F058Q36395831-13013371-9546-4741-82BF-A15A8AB6F9DBQ36404178-74CAD3C3-9960-41CD-BCCE-85BA11FB57FCQ36538834-8C50783B-FE97-461A-809D-D7BFB39DBB80Q36845999-5D6EBE65-2A89-4F43-9B4B-F7A122F37184Q37096221-17F27B81-9A20-40BA-BE3C-56325A2EAEE2Q37351948-B1759AE6-61BF-4445-8C54-E4EC4BC6B620Q37652734-26C05CEB-08CA-4825-A0A1-B910FA62FE8FQ38741327-025C3759-493C-4BBE-960D-3B6870F3B7B3Q38830109-C98C496E-E563-486E-956F-E9BDA2022952Q39157055-E36860EB-10E5-4D45-B9BA-9B23A4286E0EQ39234323-02E5E71C-7225-4FDD-8F45-9FA7EDC3764AQ40156803-43244685-5E06-4E4C-9A7D-FB2F2E865E46Q42628113-9C959567-9FCB-45F9-AF18-70D5EC71C4A7Q42753196-05C017F6-2D4F-47B9-B1F5-43B8F632A0D5
P2860
Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Monovalent virus-like particle ...... with multiple Marburg viruses.
@ast
Monovalent virus-like particle ...... with multiple Marburg viruses.
@en
Monovalent virus-like particle ...... with multiple Marburg viruses.
@nl
type
label
Monovalent virus-like particle ...... with multiple Marburg viruses.
@ast
Monovalent virus-like particle ...... with multiple Marburg viruses.
@en
Monovalent virus-like particle ...... with multiple Marburg viruses.
@nl
prefLabel
Monovalent virus-like particle ...... with multiple Marburg viruses.
@ast
Monovalent virus-like particle ...... with multiple Marburg viruses.
@en
Monovalent virus-like particle ...... with multiple Marburg viruses.
@nl
P2093
P2860
P356
P1476
Monovalent virus-like particle ...... with multiple Marburg viruses.
@en
P2093
D Anthony Alves
Dana L Swenson
Kelly L Warfield
Sadie S Coberley
Tom Larsen
P2860
P304
P356
10.1586/14760584.7.4.417
P50
P577
2008-05-01T00:00:00Z